- Home
- PDI vs IONS Comparison
PDI vs IONS Comparison
Compare PDI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDI
- IONS
- Stock Information
- Founded
- PDI 2012
- IONS 1989
- Country
- PDI United States
- IONS United States
- Employees
- PDI N/A
- IONS N/A
- Industry
- PDI Trusts Except Educational Religious and Charitable
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- PDI Finance
- IONS Health Care
- Exchange
- PDI Nasdaq
- IONS Nasdaq
- Market Cap
- PDI 6.3B
- IONS 6.0B
- IPO Year
- PDI N/A
- IONS 1991
- Fundamental
- Price
- PDI $19.79
- IONS $27.26
- Analyst Decision
- PDI
- IONS Buy
- Analyst Count
- PDI 0
- IONS 19
- Target Price
- PDI N/A
- IONS $59.24
- AVG Volume (30 Days)
- PDI 1.5M
- IONS 1.6M
- Earning Date
- PDI 01-01-0001
- IONS 05-06-2025
- Dividend Yield
- PDI 13.81%
- IONS N/A
- EPS Growth
- PDI N/A
- IONS N/A
- EPS
- PDI N/A
- IONS N/A
- Revenue
- PDI N/A
- IONS $705,138,000.00
- Revenue This Year
- PDI N/A
- IONS N/A
- Revenue Next Year
- PDI N/A
- IONS $25.71
- P/E Ratio
- PDI N/A
- IONS N/A
- Revenue Growth
- PDI N/A
- IONS N/A
- 52 Week Low
- PDI $15.45
- IONS $27.20
- 52 Week High
- PDI $19.60
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- PDI 52.68
- IONS 27.86
- Support Level
- PDI $19.56
- IONS $31.04
- Resistance Level
- PDI $19.96
- IONS $33.76
- Average True Range (ATR)
- PDI 0.18
- IONS 1.28
- MACD
- PDI -0.02
- IONS -0.52
- Stochastic Oscillator
- PDI 68.52
- IONS 0.86
About PDI PIMCO Dynamic Income Fund
PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests worldwide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investments include mortgage-backed securities, investment grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.